Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03099590 · ClinicalTrials.gov registry record · Phase 2

Alkontrol-herbal Effects on Alcohol Drinking

A Phase 2 study, sponsored by Mclean Hospital.

Completed
Registry status
Phase 2
Development phase
28
Enrollment target

NCT03099590: Completed Phase 2 study, sponsored by Mclean Hospital.

NCT03099590 is a Phase 2 study that has completed, run by Mclean Hospital. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03099590, a Phase 2 study, has completed, sponsored by Mclean Hospital.

COMPLETED
Registry status
Phase 2
Development phase
28 participants
Enrollment target

Study Summary

Participants will enroll in a 14-week study (2 weeks of baseline, 8 weeks of treatment, and 4 weeks of follow-up) investigating the impact that Alkontrol-herbal (Isoflavone; Kudzu) has on alcohol intake in a population seeking treatment for an alcohol use disorder.

Primary Outcome

percent days abstinent from alcohol

Interventions

  • DIETARY_SUPPLEMENT Placebo control
  • DIETARY_SUPPLEMENT kudzu extract, puerarin

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2018-01-01
Est. Completion 2020-07-01
Phase Phase 2
Mclean Hospital

140 total trials

What the finished NCT03099590 record still lists

NCT03099590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo control is the first listed.

NCT03099590 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03099590 about?

NCT03099590 is a clinical study titled "Alkontrol-herbal Effects on Alcohol Drinking". Participants will enroll in a 14-week study (2 weeks of baseline, 8 weeks of treatment, and 4 weeks of follow-up) investigating the impact that Alkontrol-herbal (Isoflavone; Kudzu) has on alcohol intake in a population seeking treatment for an alcohol use disorder.

What is the current status of trial NCT03099590?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2018-01-01. Estimated completion is 2020-07-01.

What interventions are being tested in trial NCT03099590?

The interventions under investigation include: Placebo control (DIETARY_SUPPLEMENT), kudzu extract, puerarin (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03099590?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03099590's enrollment target sits among peer trials

28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03099590, the US trial registry maintained by the National Library of Medicine. NCT03099590 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.